Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Researchers Discover Immune System’s ‘Trojan Horse’

By Drug Discovery Trends Editor | August 3, 2015

Viral replication: The virion enters the cell and begins the process of replication. cGAS detects the viral DNA and creates cGAMP. As the virus buds and breaks away from the cell, cGAMP is incorporated within the envelope of the new virion. The virion infects a further cell and in doing so releases the cGAMP which triggers that cell's immune response. (Credit: designua via Shutterstock)Scientists already knew that when a virus containing or producing DNA enters a cell in the body it is detected by a protein called cGAS. This in turn produces a small signalling molecule called cGAMP which acts as what’s known as a second messenger, activating other elements of the body’s immune response. Now, the Oxford team have discovered that as some viruses replicate, they incorporate cGAMP, meaning that as they infect new cells the cGAMP immediately prompts an immune response.

Professor Jan Rehwinkel from the MRC Human Immunology Unit, within Oxford University’s Radcliffe Department of Medicine, explained: “We hypothesised that as the virus replicated, cGAMP was incorporated and carried to the next cell to be infected. This may not have been spotted before because in the lab researchers tend to use cells that are free of cGAS and therefore unable to produce cGAMP.”

“By putting cGAS back into some of these cells, we were able to compare what happened as the virus moved to infect new cells. Viruses from cells that had been loaded with cGAS and could produce cGAMP stimulated a much more potent immune response when they moved into new cells than viruses that had come from cells without cGAS.”

“This confirmed our hypothesis in cells with artificially high levels of cGAS but we needed to also test it using cells with naturally occurring levels of the protein. We used cells from mice and compared these to cells from genetically engineered mice that were cGAS free. The finding was the same – where cGAMP was produced, it travelled within the virus particles.”

“It is not yet clear whether cells are tagging these virus particles deliberately or whether it is simply a by-product of how viruses replicate.”

The Oxford team are now investigating whether the research could be used to improve a class of vaccines. Viral vectored vaccines are genetically engineered virus particles designed to prompt an immune response against particular diseases. The researchers will look at whether by loading these particles with cGAMP it is possible to stimulate a bigger immune response, making such vaccines more effective.

The paper describing this research, Viruses transfer the antiviral second messenger cGAMP between cells, is published in Science Express.

Similar results have been obtained by a group of scientists led by Professor Nicolas Manel at the Institut Curie, Paris, and will be published simultaneously.

cGAMP’s role in the immune response

1. cGAS (Cyclic GMP-AMP synthase) detects viruses containing or producing DNA and in turn produces cGAMP.
2. cGAMP (Cyclic guanosine monophosphate–adenosine monophosphate) binds to STING (Stimulator of interferon genes).
3. STING drives production of type I interferons, which regulate the immune system’s response to virus infection.

Source: University of Oxford


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE